Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerliponase alfa in CLN2 Disease (Study 190-201)
NCT01907087Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Sep 2013
- Primary completion
- Nov 2015
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of cerliponase alfa in neuronal ceroid lipofuscinosis type 2 (CLN2), sponsored by BioMarin Pharmaceutical. Primary endpoint: Motor-Language Scale Score at 49 weeks. Started Sep 2013; status: completed.
02
Drugs
cerliponase alfa
03
Conditions
neuronal ceroid lipofuscinosis type 2 (CLN2)
Beyond the preview
Go deeper on NCT01907087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01907087.